Clinical Report: OTX-TKI: Inside the SOL-1 Data
Overview
The SOL-1 trial evaluated OTX-TKI (Axpaxli) against aflibercept in treatment-naïve patients with neovascular AMD. Key findings included a percentage of patients maintaining vision and time to rescue treatment.
Background
Neovascular age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, making effective treatment crucial. The SOL-1 trial evaluates OTX-TKI, a novel intravitreal hydrogel implant, against the standard of care, aflibercept, to determine its efficacy in vision maintenance and safety profile.
Data Highlights
| Parameter | OTX-TKI | Aflibercept |
|---|---|---|
| Vision Maintenance at Week 36 | 74% | 56% |
| Vision Maintenance at Week 52 | 66% | 44% |
| Rescue Treatment by Week 52 | 30% | Proportion by Week 28 |
| Mean Visual Acuity (letters) | 80 | 80 |
| Fluid Stability (nL difference) | 30 | 60 |
Key Findings
- 74% of patients in the OTX-TKI arm maintained vision at Week 36 compared to 56% in the aflibercept arm.
- At Week 52, 66% of OTX-TKI patients maintained vision versus 44% of those on aflibercept.
- 30% of patients in the OTX-TKI arm required rescue treatment by Week 52, compared to 30% in the aflibercept arm by Week 28.
- OTX-TKI demonstrated fluid stability with a 30-nL difference over 36 weeks compared to 60 nL in the aflibercept arm.
- Common adverse events were similar to those expected for intravitreal injections, with no serious treatment-related adverse events reported.
Clinical Implications
The SOL-1 trial results suggest that OTX-TKI may provide a more effective option for maintaining vision in patients with neovascular AMD compared to aflibercept. The safety profile appears favorable, with no serious adverse events reported.
Conclusion
The findings from the SOL-1 trial indicate that OTX-TKI is a promising treatment for neovascular AMD, showing superior vision maintenance and a favorable safety profile compared to aflibercept.
Related Resources & Content
- Dilsher S. Dhoot, MD, FASRS, Retinal Physician, 2026 -- OTX-TKI: Inside the SOL-1 Data
- Jim Gallagher, Retinal Physician, 2026 -- Axpaxli Superior to Aflibercept in Wet AMD Trial
- Jim Gallagher, Retinal Physician, 2025 -- OTX-TKI May Decrease Retinal Leakage in NPDR
- Age-Related Macular Degeneration Preferred Practice Pattern® - PubMed, 2025
- Retinal Physician — OTX-TKI May Decrease Retinal Leakage in NPDR
- retinal physician — OTX-TKI May Decrease Retinal Leakage in NPDR
- Age-Related Macular Degeneration Preferred Practice Pattern® - PubMed
- Ocular Therapeutix, Inc._March 31, 2026
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.